Advanced Filters
noise

Rheumatoid Arthritis Clinical Trials

A listing of Rheumatoid Arthritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 277 clinical trials

Fexofenadine in Patients With Active Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying …

18 - 60 years of age All Phase 1/2
A Al-Azhar Universiy

Pulse Steroid Injection in Refractory Rheumatoid Arthritis

Remission or low disease activity in active rheumatoid arthritis

20 - 65 years of age All Phase 3

L-carnitine Supplementation in Rheumatoid Arthritis Patients

This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.

18 - 60 years of age All Phase 2
M Mostafa M Bahaa, PhD

Paroxetine Safety and Efficacy in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic chronic auto-inflammatory disorder which imposes a remarkable burden of morbidity and mortality on global health. The complex interaction between genetics, environment, and immunological response contribute to RA pathogenesis. Current treatment comprises conventional disease-modifying anti-rheumatic drugs (DMARDs) followed by biological DMARDs, if necessary, to achieve …

23 - 57 years of age All Phase 3
Y Yao-Wei Zou

Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is the leading cause of disability in Chinese women. We established a synovial pathology queue in the early stage and proposed a new synovial immunopathology classification. We found that baseline myeloid stromal RA patients had severe conditions and poor outcome. Early identification of synovial myeloid stromal RA …

18 - 65 years of age All Phase N/A
M Monica Guma, M.D, PHD

Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

In a previous exploratory study, the investigators observed an effect on disease activity outcomes of anti-inflammatory diet. The investigators also observed change in microbiome and circulating metabolites. The current study will determine whether or not the addition of anti-inflammatory diet improves the clinical outcomes in participants with rheumatoid arthritis, and …

18 years of age All Phase N/A
Q Qian Wang, MD

Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

This is a single-center, single-arm, prospective study on the efficacy and safety of Bortezomib in addition to standard therapy in patients with refractory rheumatoid arthritis.

18 - 70 years of age All Phase N/A
E Emmanuelle DERNIS, MD

Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis

In rheumatoid arthritis (RA), the consensual 1st line conventional synthetic disease modifying antirheumatic drugs (csDMARD) of RA is methotrexate (MTX). In case of contra-indication or intolerance to MTX, leflunomide is an alternative. If the treatment target is not achieved with csDMARD strategy, addition of a biological DMARD (TNF inhibitors, anti-Interleukin …

18 years of age All Phase 3
E Emmanuelle DERNIS, MD

Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

As stated by the European League Against Rheumatism (EULAR) and the Société Française de Rhumatologie (SFR), treatment of patients with rheumatoid arthritis (RA) should target sustained remission or at least low disease activity. However, despite significant advances based on various combinations of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and biologic …

18 - 65 years of age All Phase 3
B Bridget Kramer

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

This is a 16-week, open-label study to identify factors that help predict clinical responses to DMARD therapies for RA (Rheumatoid Arthritis) patients. All patients will receive a starting dose of DMARD medication(s) which may be adjusted by the investigator as needed. If a subject becomes intolerant to a DMARD medication …

19 years of age All Phase 3

Simplify language using AI